Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

The success of glucagon-like peptide receptor antagonists (GLP-1RAs) over the last few years stands out in the pharmaceutical landscape due to this class’s potential to grow in more than one disorder. While the leading GLP-1RAs were initially approved for type 2 diabetes, they have since been indicated for wider groups of patients. 

This month’s cover story looks at how pharmaceutical and biotech companies are strategically approaching the wide umbrella of metabolic disorders to plan drug development. 

Also in this issue, an interview delves into NVIDIA’s strategy for growing its artificial intelligence (AI) prowess in the healthcare sector, and a feature investigates the robust dealmaking in the antibody drug conjugate (ADC) space. 

All this, along with the latest news and deals in the pharmaceutical landscape.

Manasi Vaidya, editor